Journal of Bioequivalence & Bioavailability

Fang L

Publications

• Research Article
  Bioequivalence of the Rilpivirine/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen
  Author(s): Zack J, Chuck S, Chu H, Graham H, Cao H, Tijerina M, West S, Fang L, Quirk E and Kearney BZack J, Chuck S, Chu H, Graham H, Cao H, Tijerina M, West S, Fang L, Quirk E and Kearney B
  
  Rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF) is the next advancement in once-daily antiretroviral single-tablet regimen (STR) for the treatment of HIV-1 in adults. Tenofovir disoproxil fumarate (TDF), an oral prodrug of tenofovir (TFV), is a preferred nucleotide reverse transcriptase inhibitor, but it is also associated with nephrotoxicity and reduced bone mineral density (BMD). TDF has been replaced by tenofovir alafenamide (TAF), a novel, oral prodrug of TFV with a different metabolic pathway leading to 91% lower circulating plasma concentrations of TFV. Differences with TAF have resulted in less nephrotoxicity and less reduction or increase in BMD in clinical trials. This study evaluated the pharmacokinetics and bioequivalence of the components of RPV/FTC/TAF (25/200/25 mg) STR to the references of RPV (25 mg) single tablet and elvitegr.. View More»
  DOI: 10.4172/jbb.1000266

  Abstract PDF